Applications of 2,6-Dihydroxy-3-Methylpurine in Industrial Manufacturing

2,6-Dihydroxy-3-Methylpurine serves as a specialized chemical intermediate across the pharmaceutical, biochemical, and analytical reagent industries. As the original manufacturer, we supply high-grade material that meets global industry benchmarks for downstream integration. Below, we outline key application scenarios based on verified industrial practices.

1. Pharmaceutical API Synthesis: Antigout Drug Intermediates

Pharmaceutical manufacturers utilize 2,6-Dihydroxy-3-Methylpurine as a selective intermediate in the synthesis of xanthine oxidase inhibitors for gout treatment. The purity and impurity profile requirements for this segment are tightly regulated, especially where the compound enters into the key heterocyclic assembly stage for producing finished APIs. Our customers apply this material in controlled batch reactions, optimizing input to maintain downstream product yield and regulatory compliance across multiple pilot and full-scale lines.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• US FDA cGMP 21 CFR Part 210/211
• European Pharmacopoeia (Ph. Eur.) Monographs
• China Pharmacopeia Standards (ChP)

Typical usage ratio

• 1.5%–5.5% of the total reaction mass, adjusted based on stoichiometry and target yield

Downstream process integration

• Active ingredient synthesis—input during the heterocycle formation and specific methylation or hydroxylation steps prior to purification

Final product types

• Finished xanthine oxidase inhibitor active pharmaceutical ingredients (APIs), such as allopurinol analogs
• Formulated oral solid-dosage tables for hyperuricemia and chronic gout

2. Biotechnology: Substrate in Enzyme Activity Assays

Biotech firms employ this compound as a substrate in laboratory assays to monitor xanthine oxidase activity and related metabolic enzyme testing. The precise concentration of substrate is essential for reproducibility and accurate analytical outputs. This downstream use helps clinical labs, CROs, and hospital labs to validate enzyme inhibitors, establish pharmacokinetic profiles, and perform target-based screenings, following globally recognized laboratory practices.

Industry compliance standards

• ISO 13485 for medical devices and in vitro diagnostics
• GLP (Good Laboratory Practice), OECD Principles
• CLSI guidelines (Clinical & Laboratory Standards Institute)

Typical usage ratio

• 10–100 μM in reaction buffer, scaled to assay kit or automated platform volume

Downstream process integration

• Addition as a substrate to enzyme reaction mixtures during activity assays or inhibitor profiling, followed by spectrophotometric or fluorometric detection

Final product types

• Xanthine oxidase activity assay kits
• Pre-formulated laboratory reagent packs
• Bulk substrate reagents for automated analyzers

3. Analytical Reagents: Reference Standards and R&D Tools

Chemical analysis laboratories, academic research groups, and QC teams deploy 2,6-Dihydroxy-3-Methylpurine as a reference compound for purine derivative identification and quantitation via HPLC, LC-MS/MS, and UV-VIS instrumentation. Accurate application at defined reference concentrations assures system suitability, calibration, and traceability within the quality assurance workflow, essential for audit and regulatory submissions.

Industry compliance standards

• ISO/IEC 17025 for laboratory competence
• USP General Chapters for Reference Standards
• Ph. Eur. Reference Standards Guidelines

Typical usage ratio

• 0.01–0.5 mg/mL in analytical standard preparation, determined by detection method and matrix complexity

Downstream process integration

• Preparation of reference and calibration solutions for purity, identification, and quantitation by validated chromatographic or spectrometric methods

Final product types

• Ready-to-use reference standards vials
• Calibration solutions for chromatographic and spectrometric QC systems

4. Fine Chemicals: Starting Material for Purine Derivative Synthesis

Producers of purine analogues require a consistent supply of 2,6-Dihydroxy-3-Methylpurine for subsequent nucleoside/nucleotide and heterocyclic derivative manufacturing. This intermediate input manages ring substitution patterns essential for SAR study compound libraries and the development of diagnostic probes. Controlled addition during early-stage synthesis ensures downstream selectivity and minimized byproduct formation in multi-step reactions.

Industry compliance standards

• ISO 9001:2015 Quality Management
• Chemical Plant Environmental, Health, and Safety (EHS) compliance under national regulations

Typical usage ratio

• 3%–7% w/w in synthesis setup depending on molecular target and designed substitution reactions

Downstream process integration

• Initial coupling and modification stage, typically entering the first or second synthetic transformation for diverse purine derivatives

Final product types

• Custom purine heterocycle derivatives
• Research-scale pharmacological probe compounds
• Building blocks for commercial R&D compound libraries